Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trialMarc E. Rothenberg, Arsalan Shabbir, Evan S. Dellon et al.|The Lancet. Gastroenterology & hepatology|2023Cited by 100
Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS TrialMirna Chehade, Arsalan Shabbir, Evan S. Dellon et al.|Journal of Allergy and Clinical Immunology|2024Cited by 7
605 DUPILUMAB IMPROVES HISTOLOGIC AND ENDOSCOPIC ASPECTS OF EOSINOPHILIC ESOPHAGITIS IN CHILDREN AGED 1-11 YEARS IN THE PHASE 3 EOE KIDS TRIALMirna Chehade, Arsalan Shabbir, Marc E. Rothenberg et al.|Gastroenterology|2023Cited by 2
Dupilumab Normalized The Expression Of Genes Dysregulated In Eosinophilic Esophagitis (EoE) In Esophageal Biopsies From A Clinical Trial Of Children Aged 1–11 YearsMarc E. Rothenberg, Jennifer D. Hamilton, Christopher Parrish et al.|Journal of Allergy and Clinical Immunology|2024Cited by 1